{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T04:29:00Z","timestamp":1726806540431},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1053\/j.gastro.2024.07.005","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T05:59:19Z","timestamp":1720936759000},"page":"841-842","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shot Heard Around the World? Subcutaneous Infliximab as Maintenance Therapy for Inflammatory Bowel Disease"],"prefix":"10.1053","volume":"167","author":[{"given":"Catalina","family":"Mulanax","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando S.","family":"Velayos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Lim","key":"10.1053\/j.gastro.2024.07.005_bib1"},{"key":"10.1053\/j.gastro.2024.07.005_bib2","first-page":"1234","article-title":"A\u00a0systematic review of U.S. biosimilar approvals: what evidence does the FDA require and how are manufacturers responding?","volume":"23","author":"Hung","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1053\/j.gastro.2024.07.005_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11894-023-00913-5","article-title":"biosimilars in IBD: what every clinician needs to know","volume":"26","author":"Angyal","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1053\/j.gastro.2024.07.005_bib4","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s10620-021-07114-y","article-title":"Does similarity breed contempt? A review of the use of biosimilars in inflammatory bowel disease","volume":"66","author":"Bhat","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.07.005_bib5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.005_bib6","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.005_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","volume":"11","author":"Vermeire","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.005_bib8","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 1","key":"10.1053\/j.gastro.2024.07.005_bib9","doi-asserted-by":"crossref","first-page":"i1614","DOI":"10.1093\/ecco-jcc\/jjad212.1004","article-title":"P874 Impact of immunogenicity on clinical outcomes in patients with Crohn\u2019s disease receiving maintenance treatment with subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD study","volume":"18","author":"Colombel","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.07.005_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40261-022-01162-6","article-title":"Re-routing infliximab therapy: subcutaneous infliximab opens a path towards greater convenience and clinical benefit","volume":"42","author":"Alten","year":"2022","journal-title":"Clin Drug Investig"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524052077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524052077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T19:01:32Z","timestamp":1726772492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524052077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0016508524052077"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.07.005","relation":{},"ISSN":["0016-5085"],"issn-type":[{"type":"print","value":"0016-5085"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shot Heard Around the World? Subcutaneous Infliximab as Maintenance Therapy for Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.05.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}